EUCTR2017-001518-27-Outside-EU/EEA进行中（未招募）1 期
Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and AdolescentsPIP decision number: P/116/2017PIP decision number: P/0117/2021 for Pifeltro PIP decision number: P/0176/2021 for Delstrigo
IAID, NICHD, NIMH0 个研究点开始时间: 2018年2月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Weight greater than or equal 35 kg at entry
- •If not of legal age to provide independent informed consent: Parent or guardian was willing and able to provide written informed consent for study participation; in addition, when applicable per local Institutional Review Board / Ethics Committee (IRB/EC) policies and procedures, potential participant was willing and able to provide written informed assent for study participation. If of legal age to provide independent informed consent as determined by site Standard Operating Procedures (SOPs) and consistent with site IRB/EC policies and procedures: Potential participant was willing and able to provide written informed consent for study participation
- •Confirmed HIV-1-infection based on documented testing of two samples collected at different time points.
- •Antiretroviral therapy (ART) exposure, virologic suppression, and resistance requirements, as follows:
- •ART exposure requirements, based on individual or parent/guardian's report and, if available, confirmed by medical records:
- •At entry, receiving combination ART with raltegravir (RAL) or dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs); AND
- •At entry, had not received non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitor (PIs), or cobicistat within the previous 30 days; AND
- •Virologic suppression, as documented in medical records and as defined by:
- •One or more HIV RNA polymerase chain reaction (PCR) result below the level of quantification (BLLQ) within 15 months prior to enrollment, AND
- •If any HIV RNA PCR tests had been done within 3 months prior to enrollment, all results were below the level of quantification, AND
- •HIV RNA PCR result less than 40 copies/mL at screening.
- •Cohort 2 ART-naive
- •ART exposure requirements, based on individual or parent/guardian's report and, if available, confirmed by medical records:
- •At entry, received no antiretrovirals (ARVs) for treatment of HIV infection including investigational agents (prior receipt of ARVs for prevention of perinatal transmission was permitted); AND
- •Screening genotypic resistance test results indicated susceptibility to doravirine (DOR), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) (see the protocol for more information; result must be available prior to enrollment); AND
- •If available, as documented in medical records, any prior genotypic resistance test result indicated susceptibility to DOR, TDF, and 3TC.
- •Cohort 2 ART-experienced
- •ART exposure requirements, based on individual or parent/guardian's report and, if available, confirmed by medical records:
- •No previous history of change in ARVs due to clinical or virologic failure, in the opinion of the site investigator or designee; AND
- •Virologic suppression, as documented in medical record and as defined by:
- •One or more HIV RNA PCR result BLLQ within 15 months prior to enrollment, AND
- •If any HIV RNA PCR tests had been done within 3 months prior to enrollment, all results were below the level of quantification, AND
- •HIV RNA PCR result less than 40 copies/mL at screening; AND
- •If available, as documented in medical records, any prior genotypic resistance test result indicated susceptibility to DOR, TDF, and 3TC.
- •Grade 2 or lower hemoglobin, aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, and lipase on specimens obtained at screening
- •For Cohort 2 only, grade 2 or lower creatinine, proteinuria, a
排除标准
- •Evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or other signs or symptoms of advanced liver diseases.
- •For Cohort 2 only, detectable hepatitis C virus (HCV) by RNA PCR or current or planned treatment with direct antiviral agent for HCV.
- •Presence of any active AIDS-defining opportunistic infection
- •History of malignancy (ever), with the exception of localized malignancies such as squamous cell or basal cell carcinoma of the skin
- •Clinical evidence of pancreatitis, as determined by the clinician (at entry)
- •Use of nafcillin, dicloxacillin, or any of the prohibited medications, within 30 days prior to study entry
- •For females, currently breastfeeding an infant at entry
- •Enrolled in another clinical trial of an investigational agent, device, or vaccine
- •Unlikely to adhere to the study procedures or keep appointments, in the opinion of the site investigator or designee
- •Used, or anticipates using, chronic systemic immunosuppressive agents or systemic interferon (e.g., for treatment of HCV infection) within 30 days prior to study entry.
- •Diagnosed with current active tuberculosis and/or was currently being treated with a rifampicin-containing regimen
- •Individual had any other condition, that in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives
研究者
相似试验
招募中
1 期
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 ExpressioAdvanced Malignancies Associated with EphA2 ExpressionMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2024-510655-36-00Bicycletx Limited288
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660:cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-ITASTEX PHARMACEUTICALS230
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-GBAstex Pharmaceuticals, Inc.230
招募中
2 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.2024-516679-33-00Taiho Oncology Inc.16
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-HUAstex Pharmaceuticals, Inc.230